I. Consensus definition of PCOS--2 or more of the following (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil. Steril. 81:19, 2004)
- Oligo- or anovlulation
- Clinical and/or biochemical signs of hyperandrogenism
- Polycystic ovaries and exclusion of other etiologies (e.g. congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)
II. Clinical features--Familial tendency has been suggested in some studies
- Hyperandrogenism
- Hirsutism, acne, male-pattern alopecia
- Elevated serum testosterone, androstenedione (us 50-150% higher than nl; can have nl seru, testosterone but elevated free testosterone)
- Probably ovarian in origin (as opposed to adrenal)
- Anovulation
- Not universal! There are women with polycystic ovaries and hyperandrogenism who have nl periods
- Amenorrhea, oligomenorrhea, or DUB
- Infertility
- Elevated LH (FSH us. low or nl); prob. secondary to ovarian dysfunction
- Have high levels of unopposed estrogen; this may put women at risk of endometrial carcinoma
- Obesity (common but not universal)
- Polycystic ovaries
- 22% of 257 "nl" volunteers had polycystic ovaries on u/s, but 94% of them had at least 1 symptom of PCOD, e.g. irreg. menses, hirsutism
- Hyperinsulinemia and insulin resistance
- Unclear why
- Doesn't seem to occur in women with polycystic ovaries and hyperandrogenism but nl periods!
- Independent of obesity
- Can see acanthosis nigricans on Px; this helps to r/o adrenal androgen-secreting tumor as cause of hyperandrogenism
- Risk of Type II DM seven times greater than gen'l population!
- May be the cause of the hyperandrogenism, both directly from hyperinsulinemia and through decreasing synthesis of sex hormone-binding globulin
III. Diff. dx
- Must distinguish from other hyperandrogenic states
- If serum testosterone > 200ng/dl suggests androgen secreting tumor
- If serum DHEA-S (dehydroepiandrosterone sulfate) > 7,000ng/dl suggests adrenal tumor
- If serum 17-hydroxyprogesterone > 800ng/dl suggests 21-hydroxylase deficiency; if < 200-800, suggests CAH
- Note that Valproic Acid may cause PCOS
IV. Treatment
- Weight loss--Will tend to improve all aspects of the disease
- For infertility, try to induce ovulation
- Antiestrogens, e.g. Clomiphine
- Insulin-Sensitizing agents
- Metformin
- Metformin 500mg/d resulted in much higher rates of ovulation than placebo in one 5wk study of 61 women with PCOD and infertility (NEJM 338:1876, 1998--JWWH)
- Metformin increased ovulation rate in women with PCOS and anovulation (Fertil. Steril. 75:310, 2001--JW)
- Metformin 500mg TID ass'd with sig. improvements in hirsutism, obesity, and menstrual cycle frequency (Eur. J. Endocrin. 147:217, 2002--cited in Med. Lett. 45:35, 2003)
- 410 pts with PCOD randomized to Troglitazone 150-600mg/d vs. placebo x 44wks. Troglitazone tx ass'd with dose-dependent increase in ovulation rates, sig. more pregnancies, sig. less hirsutism, and sig. lower fasting insulin and free testosterone levels. (J. Clin. Endo. Metab. 86:1626, 2001--JW)
- Gonadotropins-low-dose regimens may reduce risk of multiple gestation
- Pulsatile GnRH administration
- Laparascopic laser diathermy (no better than gonadotropin tx in one head-to-head study; Clin. Endocrinol. 33:585, 1990)
- For oligo- or amenorrhea or DUB
- Since risk of endometrial Ca is theoretically there, advisable to cycle with Oral Contraceptives or just cyclical progestins
- Avoid progestins with intrinsic androgenic activity b/c may worsen androgenic sx of PCOD
- OC's may be better than just progestins because the exogenous estrogens may reduce ovarian androgen production
- If not, consider regular u/s to monitor endometrial thickness (no clinical trials, just author's suggestion)
- For androgenic sx
- Spironolactone (may cause erratic uterine bleeding, so sometimes given along with OC's
- In a randomized trial in 69 women with PCOS randomized to spironolactone 50mg/d vs. metformin 1000mg/d, spironolactone was ass'd with greater improvements in hirsutism, increased frequency of menstrual periods, and less side effects (J. Clin. Endocr. Metab. 89:2756, 2004--JW)
- Note--antiandrogens can cause lethargy, mood swings, loss of libido
- Can take up to 5 mos to show change in hair growth; maximal effects may take 18mos or longer
V. Other
- Consider screening for glucose intolerance, e.g. w/ HbA1c or GTT, esp. if obese
- Screen for dyslipidemias
(NEJM333:853, 1994)